Singular Genomics Systems, Inc. (NASDAQ: OMIC) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $0.85 to $0.75. They now have a "neutral" rating on the stock.
Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results [Yahoo! Finance]
Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results
Labroots Announces the 12th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2024 [Yahoo! Finance]
Singular Genomics to Report First Quarter 2024 Financial Results on May 14, 2024